89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors

Albert J. Chang, Ravindra De Silva, Sandeep Jain, Kimberley Lears, Buck Rogers, Suzanne Lapi

Research output: Contribution to journalArticle

Abstract

The human epidermal growth factor receptor 2 (HER2/neu) is overexpressed in 20-30% of breast cancers and is associated with tumor growth, angiogenesis, and development of distant metastases. Trastuzumab, an anti-HER2 monoclonal antibody, is used for the treatment of HER2 positive breast cancer and clinical efficacy of this agent is dependent on HER2 expression. Targeted PET imaging of HER2 with radiolabeled trastuzumab may be used to determine HER2 expression levels and guide therapy selection. The purpose of the current study was to evaluate a facile 89Zr-trastuzumab preparation method that can be efficiently applied for clinical grade production. Also, relative HER2 expression levels in orthotopic and metastatic breast cancer models were assessed by PET imaging using the 89Zr-trastuzumab produced by this simpler method.

Original languageEnglish (US)
Pages (from-to)79-93
Number of pages15
JournalPharmaceuticals
Volume5
Issue number1
DOIs
StatePublished - Jan 5 2012
Externally publishedYes

Fingerprint

Breast Neoplasms
Growth and Development
Monoclonal Antibodies
Neoplasm Metastasis
zirconium-89-trastuzumab
Neoplasms
Trastuzumab
Therapeutics
human ERBB2 protein

Keywords

  • Zr
  • HER2
  • ImmunoPET
  • PET

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Cite this

89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors. / Chang, Albert J.; De Silva, Ravindra; Jain, Sandeep; Lears, Kimberley; Rogers, Buck; Lapi, Suzanne.

In: Pharmaceuticals, Vol. 5, No. 1, 05.01.2012, p. 79-93.

Research output: Contribution to journalArticle

Chang, Albert J. ; De Silva, Ravindra ; Jain, Sandeep ; Lears, Kimberley ; Rogers, Buck ; Lapi, Suzanne. / 89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors. In: Pharmaceuticals. 2012 ; Vol. 5, No. 1. pp. 79-93.
@article{0483ef2613e2476c9139962aec90781e,
title = "89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors",
abstract = "The human epidermal growth factor receptor 2 (HER2/neu) is overexpressed in 20-30{\%} of breast cancers and is associated with tumor growth, angiogenesis, and development of distant metastases. Trastuzumab, an anti-HER2 monoclonal antibody, is used for the treatment of HER2 positive breast cancer and clinical efficacy of this agent is dependent on HER2 expression. Targeted PET imaging of HER2 with radiolabeled trastuzumab may be used to determine HER2 expression levels and guide therapy selection. The purpose of the current study was to evaluate a facile 89Zr-trastuzumab preparation method that can be efficiently applied for clinical grade production. Also, relative HER2 expression levels in orthotopic and metastatic breast cancer models were assessed by PET imaging using the 89Zr-trastuzumab produced by this simpler method.",
keywords = "Zr, HER2, ImmunoPET, PET",
author = "Chang, {Albert J.} and {De Silva}, Ravindra and Sandeep Jain and Kimberley Lears and Buck Rogers and Suzanne Lapi",
year = "2012",
month = "1",
day = "5",
doi = "10.3390/ph5010079",
language = "English (US)",
volume = "5",
pages = "79--93",
journal = "Pharmaceuticals",
issn = "1424-8247",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

TY - JOUR

T1 - 89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors

AU - Chang, Albert J.

AU - De Silva, Ravindra

AU - Jain, Sandeep

AU - Lears, Kimberley

AU - Rogers, Buck

AU - Lapi, Suzanne

PY - 2012/1/5

Y1 - 2012/1/5

N2 - The human epidermal growth factor receptor 2 (HER2/neu) is overexpressed in 20-30% of breast cancers and is associated with tumor growth, angiogenesis, and development of distant metastases. Trastuzumab, an anti-HER2 monoclonal antibody, is used for the treatment of HER2 positive breast cancer and clinical efficacy of this agent is dependent on HER2 expression. Targeted PET imaging of HER2 with radiolabeled trastuzumab may be used to determine HER2 expression levels and guide therapy selection. The purpose of the current study was to evaluate a facile 89Zr-trastuzumab preparation method that can be efficiently applied for clinical grade production. Also, relative HER2 expression levels in orthotopic and metastatic breast cancer models were assessed by PET imaging using the 89Zr-trastuzumab produced by this simpler method.

AB - The human epidermal growth factor receptor 2 (HER2/neu) is overexpressed in 20-30% of breast cancers and is associated with tumor growth, angiogenesis, and development of distant metastases. Trastuzumab, an anti-HER2 monoclonal antibody, is used for the treatment of HER2 positive breast cancer and clinical efficacy of this agent is dependent on HER2 expression. Targeted PET imaging of HER2 with radiolabeled trastuzumab may be used to determine HER2 expression levels and guide therapy selection. The purpose of the current study was to evaluate a facile 89Zr-trastuzumab preparation method that can be efficiently applied for clinical grade production. Also, relative HER2 expression levels in orthotopic and metastatic breast cancer models were assessed by PET imaging using the 89Zr-trastuzumab produced by this simpler method.

KW - Zr

KW - HER2

KW - ImmunoPET

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=84856261443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856261443&partnerID=8YFLogxK

U2 - 10.3390/ph5010079

DO - 10.3390/ph5010079

M3 - Article

C2 - 24288044

AN - SCOPUS:84856261443

VL - 5

SP - 79

EP - 93

JO - Pharmaceuticals

JF - Pharmaceuticals

SN - 1424-8247

IS - 1

ER -